(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

Celltrion USA’s FDA-approved biosimilar adalimumab-aaty, has been added program to the Costco member prescription program. Adalimumab-aaty is a high-concentration (100mg/mL) and citrate-free ...

Boehringer Ingelheim and GoodRx are launching a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Biosimilars demonstrate comparable drug survival and safety with adalimumab among new users, but patients switching from Humira (the originator product) to biosimilars had a 35% higher discontinuation ...

Medicare Part D coverage is never static, but 2026 is shaping up to be a particularly volatile year for formularies.

Evio Pharmacy Solutions, the for-profit pharmacy solutions company formed by five Blue Cross & Blue Shield licensees, said today it has entered a unique direct-purchase deal for a cheaper version of ...

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for these ...

(Reuters) - UnitedHealth Group said on Tuesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and ...